XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004
|
Citation:
|
XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004
|
XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004
|
Citation:
|
XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004
|
DownLoad: